75 results on '"Cortes, J. E."'
Search Results
2. A survey of current practices in the management of chronic myeloid leukemia (CML).
3. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.
4. A new symptom measure in chronic myeloid leukemia.
5. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.
6. Secondary malignancies in essential thrombocythemia and polycythemia vera: A retrospective analysis of 437 patients from a single institution.
7. Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes.
8. Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).
9. Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes.
10. Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure.
11. Open-label study evaluating change in chronic low-grade (LG) non-hematologic (heme) adverse events (AEs) in Philadelphia positive (Ph+) CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL).
12. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes.
13. CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML).
14. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL).
15. A single-arm, open-label, multi-center study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
16. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
17. Risk of progression to myelofibrosis and acute myeloid leukemia in patients with essential thrombocythemia and polycythemia vera with prior malignancy.
18. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
19. Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML.
20. Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.
21. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
22. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis.
23. Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.
24. Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.
25. Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.
26. Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.
27. Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC).
28. Dynamic of morphologic and molecular remission in patients (pts) with APL treated with frontline ATRA and arsenic trioxide (ATO).
29. Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).
30. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).
31. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS).
32. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).
33. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.
34. CPX-351: A randomized phase IIb study first-relapse patients younger than age 65.
35. Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR).
36. Symptom burden in chronic myeloid leukemia (CML).
37. Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.
38. CPX-351 IN AML after failed induction with cytarabine and daunorubicin.
39. Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).
40. Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.
41. United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry.
42. Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
43. Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.
44. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.
45. Association of lymphocytosis following treatment with dasatinib with response and outcome.
46. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial
47. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML)
48. Phase II study of thymoglobulin, cyclosporine and G-CSF for initial treatment of aplastic anemia and low risk myelodysplastic syndrome
49. Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure
50. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.